Prognosis and Treatment of Myelodysplastic Syndromes: Novel Therapeutic Strategies BASED ON A PRESENTATION BY ALAN F. LIST, MD
نویسندگان
چکیده
Letter From the Editors W elcome to the 2004 Pharmacy Edition of Frontiers in HematOncology, a report designed to address concerns of the health-system pharmacist. This issue contains a Continuing Education (CE) Program reviewing 2 important symposia—”Prognosis and Treatment of Myelodysplastic Syndromes (MDS),” held at the 2004 Making a Difference in Oncology (MADONC) conference in St Petersburg, Fla, and “Challenges in Anticoagulation Therapy: A Case-Based Approach,” held at the 2003 Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) in New Orleans, La. At MADONC, Alan List reviewed MDS prognosis and the status of novel therapies. At ASHP, Edith Nutescu, Henry Bussey, Jr., and David Frame discussed newer anticoagulant agents and the emerging role of low-molecular-weight heparins (LMWHs) in cancer. These symposia provided the content for this CE Program, accredited by the University of Illinois at Chicago College of Pharmacy. This issue also includes news from the 2003 Annual Meeting of the American Society of Hematology (ASH) in San Diego, Calif. Your comments on this issue or suggestions for future issues will be appreciated. Please write to the Editors at Frontiers in HematOncology, BioScience Communications, 1500 Broadway, New York, NY 10036, USA, or fax us at +1-212-704-0120. ■
منابع مشابه
Challenges in myelodysplastic syndromes: raising awareness and promoting new insight in therapeutic options.
متن کامل
CLINICAL TRIALS AND OBSERVATIONS Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
1Cancer Prevention and Control Division, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; 2Contractor to the National Cancer Institute (NCI), Bethesda, MD; 3Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley; 4Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston; 5Cancer Therapy Evaluation Prog...
متن کاملEvolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
Lenalidomide has emerged as an effective therapeutic alternative for the management of anemia in lower-risk myelodysplastic syndromes (MDS). Compelling results from phase I and phase II clinical studies prompted the US Food and Drug Administration to approve lenalidomide for the treatment of transfusion-dependent MDS patients with interstitial deletion of chromosome 5q [del(5q)]. Subsequently, ...
متن کاملMethyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.
No significant relationship exists between the author and the companies/organizations whose products or services may be referenced in this article. T he development of new, more effective treatment strategies for the myelodysplastic syndromes (MDS) has for the first time jettisoned the management approach away from the reliance on supportive measures alone toward one of active intervention. Coi...
متن کاملUnraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
Myelodysplastic syndromes (MDS) are characterized by bone marrow cytological dysplasia and ineffective hematopoiesis in the setting of recurrent somatic gene mutations and chromosomal abnormalities. The underlying pathogenic mechanisms that drive a common clinical phenotype from a diverse array of genetic abnormalities have only recently begun to emerge. Accumulating evidence has highlighted th...
متن کامل